Biodefense: Anthrax and Smallpox at the Research Forefront.
As the potential threat of biological terrorist attacks continuing to command the attention of governments around the globe, anthrax and smallpox remain amongst the most researched diseases in the biodefense industry, states a new report by pharmaceuticals experts GBI Research
The company’s latest study* shows that anthrax vaccines make up 24% of molecules in the biodefense industry pipeline, while smallpox, despite being eradicated in 1980, accounts for 32% of the total. Viral hemorrhagic fever, a category which amongst others encompasses the Ebola virus, represents 39% of pipeline molecules.
Anthrax and smallpox treatments remain key areas of development due to their high potential for destruction. These diseases can be easily transmitted through the air and have the capacity to inflict widespread devastation if deployed in a bioterrorist attack.
At present, Anthrax Vaccine Adsorbed (AVA) is the only licensed anthrax vaccine, but the use of alternative antimicrobials and antitoxin therapies for anthrax are being researched by the US National Institute of Allergy and Infectious Diseases (NIAID).
Dryvax is the FDA-approved vaccine for smallpox. Approximately 15 million doses of Dryvax vaccine have been stored since production stopped in 1983, however, it is speculated that should there be a biological attack involving smallpox, the available vaccine would not meet the demand. Accordingly, the NIAID has initiated a study to determine the feasibility of diluting Dryvax vaccine to make more doses available from the existing stores.
GBI Research states that the US government has allocated more than $50 billion since 2001 to address the threat of biological weapons, with funding for bioweapons-related activities focusing primarily on the research for, and the acquisition of, medicines for defense.
This report provides an in-depth analysis of the biodefense industry and examines the bioterrorist events which have resulted in Research and Development (R&D) in the industry
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GBI Research delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GBI Research can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.
Publisher: GBI Research
Reference code: GBIHC219MR
Report Price: $3500 (Single User License)NEXT ARTICLE